The Journal of Organic Chemistry
Page 18 of 19
1
2
3
4
5
6
7
8
9
GB and BD thank Brian Albrecht, Jurre Kamphorst, Andy Long, Gad Soffer, Kelli Armstrong,
and Brooke Swalm for their feedback during the preparation of this manuscript. DC, BC, DG, EL,
and JM thank Guy Falardeau for useful suggestions.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
References
1 Gubser, P. M.; Bantug, G. R.; Razik, L.; Fischer, M.; Dimeloe, S.; Hoenger, G.; Durovic, B.;
Jauch, A.; Hess, C. “Rapid effector function of memory CD8+ T cells requires an immediate-
early glycolytic switch” Nat. Immunol. 2013, 14, 1064-1072.
2 (a) Abdel-Haleem, A, M.; Lewis, N. E.; Jamshidi, N.; Mineta, K.; Gao, X.; Gojobori, T. “The
emerging facets of non-cancerous Warburg effect” Front. Endocrinol. 2017, 8, 279. (b) Liberti,
M. V.; Locasale, J. W. “The Warburg effect: how does it benefit cancer cells?” Trends Biochem.
Sci. 2016, 41, 211–218.
3 Other covalent inhibitors of GAPDH include: (a) pentalenolactone; Cane, D. E.; Sohng, J.-K.
“Inhibition of glyceraldehyde-3-phosphate dehydrogenase by pentalenolactone: kinetic and
mechanistic studies” Arch. Biochem. Biophys. 1989, 270, 50-61. (b) acivicin derivatives; Bruno,
S.; Margiotta, M.; Pinto, A.; Cullia, G.; Conti, P.; De Micheli, C.; Mozzarelli, A. “Selectivity of
3-bromo-isoxazoline inhibitors between human and Plasmodium falciparum glyceraldehyde-3-
phosphate dehydrogenases” Bioorg. Med. Chem. 2016, 24, 2654-2659. (c) isochaihulactone;
Chern, J.; Lu, C.-P.; Fang, Z.; Chang, C.-M.; Hua, K.-F.; Chen, Y.-T.; Ng, C. Y.; Chen, Y.-L. S.;
Lam, Y.; Wu, S.-H. “Affinity-driven covalent modulator of the glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) cascade” Angew. Chem. Int. Ed. 2018, 57, 7040-7045. (d) piceatannol;
Gerszon, J.; Serafin, E.; Buczkowski, A.; Michlewska, S.; Bielnicki, J. A.; Rodacka, A.
“Functional consequences of piceatannol binding to glyceraldehyde-3-phosphate
dehydrogenase” PLoS One 2018, 13, 1-18.
4 (a) Rahier, N. J.; Molinier, N.; Long, C.; Deshmukh, S. K.; Kate, A. S.; Ranadive, P.; Verekar,
S. A.; Jiotode, M.; Lavhale, R. R.; Tokdar, P.; Balakrishnan, A.; Meignan, S.; Robichon, C.;
Gomes, B.; Aussagues, Y.; Samson, A.; Sautel, F.; Bailly, C. "Anticancer activity of koningic
acid and semisynthetic derivatives" Bioorg. Med. Chem. 2015, 23, 3712-3721. (b) Kim, J. H.;
Lee, C. H. “Heptelidic acid, a sesquiterpene lactone, inhibits etoposide-induced apoptosis in
human leukemia U937 cells” J. Microbiol. Biotechnol. 2009, 8, 787-791.
5 Danishefsky, S. J.; Mantlo, N. “Total synthesis of (±)-heptelidic acid” J. Am. Chem. Soc. 1988,
110, 8129-8133.
6 (a) Krenn, M.; Urban, E. “Asymmetric synthesis of a structurally simplified analogue of the
antibiotic heptelidic acid” Monatshefte für Chemie 2002, 133, 127-137. (b) Riehs, G.; Urban, E.
“EPC synthesis of (+)-heptelidic acid” Monatshefte für Chemie 1997, 128, 281. (c) Riehs, G.;
Urban, E.; Völlenkle, H. “A key step towards EPC synthesis of (+)-heptelidic acid” Tetrahedron
1996, 52, 8725-8732. (d) Riehs, G.; Urban, E. “Asymmetric protected enoates as key
intermediates towards an EPC synthesis of (+)-heptelidic acid” Tetrahedron Lett. 1995, 36,
7233-7234. (e) Urban, E.; Riehs, G.; Knühl, G. “Enantiomerically pure 6-substituted 2-oxo-
cyclohexanecarboxylates by conjugate addition of cuprates to asymmetric shielded 2-oxo-
cyclohexenecarboxylates” Tetrahedron 1995, 51, 11149-11164.
ACS Paragon Plus Environment